- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04513912
Studie seltorexantu ve srovnání s kvetiapinem XR jako doplňková léčba k antidepresivům u dospělých a starších účastníků s těžkou depresivní poruchou s příznaky nespavosti, kteří neadekvátně reagovali na antidepresivní léčbu
Dvojitě zaslepená, randomizovaná, paralelně skupinová studie s kvetiapinem s prodlouženým uvolňováním jako komparátorem k vyhodnocení účinnosti a bezpečnosti přípravku Seltorexant 20 mg jako doplňkové léčby k antidepresivům u dospělých a starších pacientů s těžkou depresivní poruchou s příznaky nespavosti, kteří reagovali na antidepresivum
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Přehled studie
Postavení
Podmínky
Detailní popis
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, Argentina, C1405BOA
- FunDaMos
-
Buenos Aires, Argentina, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, Argentina, C1428AQK
- Hospital Fleni
-
Córdoba, Argentina, X5004AOA
- Instituto Privado Kremer
-
Córdoba, Argentina, 5000
- Fundacion Lennox
-
Córdoba, Argentina, X5006IKK
- Centro Medico Luquez
-
La Plata, Argentina, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, Argentina, 1902
- CENPIA
-
Mendoza, Argentina, M5502AWY
- CENAIN
-
San Miguel de Tucumán, Argentina, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Bruges, Belgie, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, Belgie, 9100
- AZ Nikolaas
-
-
-
-
-
Pleven, Bulharsko, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulharsko, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, Bulharsko, 7003
- Mental Health Center - Rousse
-
Sofia, Bulharsko, 1680
- Medical Center Intermedica, OOD
-
Sofia, Bulharsko, 1113
- Medical Center St. Naum
-
Sofia, Bulharsko, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, Bulharsko, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, Bulharsko, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, Bulharsko, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, Bulharsko, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, Bulharsko, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Kanada, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, Kanada, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, Kanada, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Kaunas, Litva, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, Litva, 53136
- Republic Kaunas Hospital
-
Kaunas, Litva, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, Litva, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, Litva, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, Litva, 10309
- Vilnius Mental Health Center
-
Vilnius, Litva, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, Litva, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Jelgava, Lotyšsko, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, Lotyšsko, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, Lotyšsko, LV-4601
- Hospital of Rezekne
-
Riga, Lotyšsko, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
-
-
-
Ipoh, Malajsie, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malajsie, 81200
- Hospital Permai
-
Pulau Pinang, Malajsie, 10990
- Hospital Pulau Pinang
-
Seremban, Malajsie, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Bełchatów, Polsko, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, Polsko, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, Polsko, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polsko, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, Polsko, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, Polsko, 90-368
- CCBR - Lodz - PL
-
Lublin, Polsko, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, Polsko, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, Polsko, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, Polsko, 02 957
- Instytut Psychiatrii I Neurologii
-
-
-
-
-
Engel's, Rusko, 413124
- Engels psychiatric hospital
-
Kemerovo, Rusko, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, Rusko, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, Rusko, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, Rusko, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, Rusko, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, Rusko, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, Rusko, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, Rusko, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, Rusko, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Banská Bystrica, Slovensko, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, Slovensko, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, Slovensko, 040 11
- Epamed sro
-
Liptovský Mikuláš, Slovensko, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Slovensko, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, Slovensko, 91101
- FN Trencin
-
Trenčín, Slovensko, 91108
- Pro mente sana s.r.o.
-
Žilina, Slovensko, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
-
Derby, Spojené království, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, Spojené království, M15 6SX
- Synexus
-
Harrogate, Spojené království, HG1 2PW
- Garden Valleys Resource Centre
-
London, Spojené království, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, Spojené království, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, Spojené státy, 90230
- Proscience Research Group
-
Encino, California, Spojené státy, 91316
- Pharmacology Research Institute
-
Garden Grove, California, Spojené státy, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, Spojené státy, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, Spojené státy, 90720
- Pharmacology Research Institute
-
Los Angeles, California, Spojené státy, 90025
- CalNeuro Research
-
Newport Beach, California, Spojené státy, 92660
- Pharmacology Research Institute
-
Orange, California, Spojené státy, 92868
- NRC Research Institute
-
Orange, California, Spojené státy, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, Spojené státy, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, Spojené státy, 91730
- Prospective Research Innovations Inc
-
Redlands, California, Spojené státy, 92374
- Anderson Clinical Research
-
San Diego, California, Spojené státy, 92103
- University of California at San Diego
-
Santa Ana, California, Spojené státy, 92705
- CI Trials
-
Santa Ana, California, Spojené státy, 91704
- National Research Institute
-
Santee, California, Spojené státy, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, Spojené státy, 91403
- Schuster Medical Research Institute
-
Upland, California, Spojené státy, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, Spojené státy, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, Spojené státy, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, Spojené státy, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, Spojené státy, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, Spojené státy, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, Spojené státy, 33803
- Meridien Research
-
Miami, Florida, Spojené státy, 33122
- Premier Clinical Research
-
Miami, Florida, Spojené státy, 33125
- Global Medical Institutes
-
Miami, Florida, Spojené státy, 33137
- Miami Jewish Health System
-
Orlando, Florida, Spojené státy, 32806
- Synexus Research Orlando
-
Orlando, Florida, Spojené státy, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, Spojené státy, 33612
- University of South Florida
-
The Villages, Florida, Spojené státy, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, Spojené státy, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Spojené státy, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, Spojené státy, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60634
- Chicago Research Center
-
Libertyville, Illinois, Spojené státy, 60048
- Capstone Clinical Research
-
Lisle, Illinois, Spojené státy, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, Spojené státy, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, Spojené státy, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, Spojené státy, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, Spojené státy, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, Spojené státy, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, Spojené státy, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Spojené státy, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Spojené státy, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, Spojené státy, 10128
- The Medical Research Network, LLC
-
New York, New York, Spojené státy, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, Spojené státy, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, Spojené státy, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, Spojené státy, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, Spojené státy, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, Spojené státy, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, Spojené státy, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, Spojené státy, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Spojené státy, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, Spojené státy, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, Spojené státy, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, Spojené státy, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, Spojené státy, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, Spojené státy, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, Spojené státy, 84015
- Alpine Research Organization
-
Draper, Utah, Spojené státy, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, Spojené státy, 98007
- Northwest Clinical Research Center
-
Everett, Washington, Spojené státy, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, Spojené státy, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
-
-
-
Belgrade, Srbsko, 11000
- University Clinical Center of Serbia
-
Belgrade, Srbsko, 11000
- General Hospital Euromedik
-
Belgrade, Srbsko, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, Srbsko, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, Srbsko, 11000
- Institute of Mental Health Serbia
-
Kovin, Srbsko, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Srbsko, 34000
- University Clinical Center Kragujevac
-
Niš, Srbsko, 18000
- Clinical Center Nis
-
Novi Kneževac, Srbsko, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Hlevakha, Ukrajina, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, Ukrajina, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, Ukrajina, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, Ukrajina, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, Ukrajina, 1034
- Medical Center Health and Happy
-
Nove, Ukrajina, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, Ukrajina, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, Ukrajina, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
-
-
-
Brno, Česko, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, Česko, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, Česko, 301 00
- A Shine S R O
-
Prague, Česko, 100 00
- Clintrial s r o
-
Prague, Česko, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, Česko, 10000
- AD71 s.r.o.
-
Prague, Česko, 186 00
- Institut Neuropsychiatricke pece
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
Aktivní komparátor: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Časové okno: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
Časové okno: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
Časové okno: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Časové okno: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
Časové okno: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Časové okno: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Časové okno: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Časové okno: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Časové okno: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Časové okno: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CR108810
- 42847922MDD3005 (Jiný identifikátor: Janssen Research & Development, LLC)
- 2020-000341-14 (Číslo EudraCT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .